← All trials
NCT05299931
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 10, 2021
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Mar 29, 2022
- Last posted
- Mar 29, 2022
- Enrollment
- 108
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZWLead sponsor
- Janssen Pharmaceutica NVCollaborator
- BIRD VZWOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.